Can you buy orlistat over the counter in canada

Featured Price: Low to High Price: High to Low Avg. Customer Review Newest ArrivalsSort by

Buy Alli Online - Shop Alli Products in Turkey

Search instead of -

Alli is a top weight-loss brand in Turkey,...View MoreAlli is a top weight-loss brand in Turkey, offering a range of effective products. With trusted reviews and a commitment to quality, Alli helps individuals achieve their weight-loss goals safely and efficiently.View LessRead More

Explore About Alli & Its Products

Alli is a brand of medication that is used for weight loss. It contains the active ingredient Orlistat, which blocks the absorption of fat in the body. Alli is sold over-the-counter and is meant to be used in combination with a low-fat, reduced-calorie diet and exercise program.

- Alli was launched in 2007 by GlaxoSmithKline.

- It was the first FDA-approved over-the-counter weight loss medication.

- In 2014, ownership of the brand was transferred to the British company Reckitt Benckiser.

- Alli is currently available in the United States, the United Kingdom, and Australia.

Brands Similar to Alli

Xenical is a prescription weight loss medication that also contains Orlistat as its active ingredient. It is marketed by Roche Pharmaceuticals and is available in many countries around the world.

PhenQ is a weight loss supplement that contains a blend of natural ingredients. It is marketed by a company called Wolfson Berg Limited and is available for purchase online.

Hydroxycut is a brand of weight loss supplements that are marketed by Iovate Health Sciences International. The brand offers a variety of products that contain different active ingredients, such as caffeine and green coffee extract.

Top Trending & High Rated Products of Alli

Alli Capsules

Alli Capsules are the brand's flagship product. Each capsule contains 60mg of Orlistat and is meant to be taken with meals that contain fat.

Common Questions Asked by Customers About Alli & Its Products

What is Alli used for?

Alli is used for weight loss. It works by blocking the absorption of fat in the body.

How do I take Alli?

Alli is meant to be taken with meals that contain fat. You should also follow a low-fat, reduced-calorie diet and exercise program while taking this medication.

Is Alli safe?

Alli is generally considered safe when used as directed. However, it can cause some side effects, such as diarrhea and abdominal pain.

How much weight can I expect to lose with Alli?

Studies have shown that people who take Alli in combination with a diet and exercise program can lose up to 5% of their body weight within six months.

Can I take Alli if I am pregnant or breastfeeding?

No, Alli is not recommended for use during pregnancy or breastfeeding.

Copyright © 2025 Ubuy Co. All rights reserved.

CounsellingVideoAlli Weight Loss ToolkitSmokingCocainePain Relief TabletsDrugs on Food & WineBabies & ChildrenBupropionAcetaminivated appetite and gas constipationBupropionCelecoxibDivalproexFlomaxol TamoxifenTamsulosinAcetazolamideTopical...

View more

Weight Loss SupplementFeatured PriceNotices of the safety of AlliReviews on Alternatives to Alli

Great product –

I take Alli for weight loss. Feeling down and tired after a month of taking it. I have to go to the gym regularly and have to watch my weight as well. It is a good brand name and is the only weight loss supplement out there that I have ever taken.

1. Introduction

Obesity, or the ‘least developed’, is defined as the lack of a body mass index (BMI) of 30 or greater, and it is the second most common cause of morbidity and mortality worldwide, with an estimated 1.9 billion adults aged ≥18 years worldwide.1,2,3,4 Lifestyle and dietary interventions are currently the most widely used approach for obesity management; for example, lifestyle interventions are a significant factor in the reduction of mortality in obese patients and the reduction of morbidity and mortality in patients with obesity.

The most common type 2 diabetes is the most commonly used type of diabetes in the world.3,5 As a result of the growing obesity epidemic, there is an increased demand for effective anti-diabetic medications for patients with diabetes. A recent study demonstrated that the use of the ‘antidiabetic medication’ for the treatment of obesity in patients with diabetes was associated with a decrease in mortality among patients with diabetes.6,7

A large-scale, randomized trial in which a fixed dose of the active ingredient in the main ingredient of the weight-control agent, orlistat, was administered to healthy overweight patients with type 2 diabetes found that the use of the ‘antidiabetic medication’ was associated with a reduction in the risk of death from cardiovascular causes.7,8 The study also found that there was a statistically significant reduction in the incidence of cardiovascular adverse events in patients receiving the drug (odds ratio [OR] = 3.9; 95% confidence interval [CI] = 2.6–5.6, P < 0.001).7

The use of the ‘antidiabetic medication’ for the treatment of obesity in patients with type 2 diabetes is associated with a significant reduction in the risk of cardiovascular events.7,8,9,10 The risk of adverse events associated with the use of the ‘antidiabetic medication’ in type 2 diabetes is significantly higher in patients with obesity than in those without obesity,7,10

The risk of cardiovascular adverse events was significantly higher in patients with obesity than in those without obesity,8 and the risk of death from cardiovascular causes was significantly lower in patients with obesity compared to those without obesity.10,11

The results of a study published in theJournal of Clinical Medicinefound that the use of the ‘antidiabetic medication’ for the treatment of obesity is associated with a significant reduction in the risk of cardiovascular adverse events in patients with type 2 diabetes.8,11,12,13,14,15,16 The results of the study also showed that there was a statistically significant reduction in the incidence of cardiovascular events (OR = 5.2; 95% CI = 2.9–9.1, P < 0.001) and death (OR = 3.3; 95% CI = 2.1–6.3, P < 0.001) among patients with obesity.17

There is a lot of research on the use of weight-control drugs in obesity. The most common drugs used to treat obesity include the medications and drugs that are considered as anti-obesity medications.5,18,19,20 A study in which a fixed-dose combination of the anti-obesity drug, orlistat, and the placebo, was administered to healthy overweight patients with type 2 diabetes found that the use of the anti-obesity drug, orlistat, was associated with a reduction in the risk of death from cardiovascular causes. The results of this study also showed that there was a statistically significant reduction in the incidence of cardiovascular events (OR = 3.4; 95% CI = 2.5–5.7, P < 0.001) and death (OR = 3.7; 95% CI = 2.1–5.5, P < 0.001) among patients with obesity compared to those without obesity.21,22

A study in which a fixed dose of the anti-obesity drug, orlistat, was administered to overweight patients with type 2 diabetes found that the use of the anti-obesity drug, orlistat, was associated with a reduction in the risk of mortality from cardiovascular causes.21,22,23 The results of this study also showed that there was a statistically significant reduction in the incidence of cardiovascular adverse events (OR = 4.2; 95% CI = 2.7–6.4, P < 0.001) and death (OR = 4.8; 95% CI = 2.1–9.8, P < 0.001) among patients with obesity compared to those without obesity.

Abstract

In order to reduce obesity, it is essential to develop appropriate dietary patterns that promote healthy lifestyle choices. However, current pharmacotherapies, and their potential for weight-loss effects, are limited by their potential for weight loss. The aim of this study was to assess the effects of a clinically-relevant weight-loss program on body composition and a non-obese male with obesity (obese/nonobese) on the following metabolic and nutritional parameters: glucose, lipids, lipoproteins and insulin, and lipid profiles: fasting plasma lipids and insulin. We then compared the effects of a clinically-relevant weight-loss program with orlistat, a lipophilic lipase inhibitor, on both parameters. Body weight, fat mass, and lean mass of the male subjects who received a clinically-relevant weight-loss program were assessed using a 12-week weight-loss trial. A total of 60 subjects who received a clinically-relevant weight-loss program and orlistat were enrolled for the study. The participants received a prescription diet for a 6-week trial and received a placebo for a 12-week trial. At the end of each 6-week trial, the body weight, fat mass, lean mass and fat percentage of the subjects were calculated. In the randomized control trial, body weight was significantly higher in the orlistat group (8.8 lb) than in the placebo group (5.8 lb). In the placebo-controlled trial, body weight was significantly higher in the orlistat group (3.9 lb) than in the placebo group (2.1 lb). The orlistat-treated subjects lost an average of 6.9% of their body weight in 6 weeks. In the orlistat-treated groups, body weight, fat mass and lean mass was significantly higher in the placebo-controlled trial (2.9 lb) than in the placebo-controlled trial (2.6 lb). The orlistat-treated subjects had a significantly greater reduction in the fasting plasma lipids than the placebo-treated subjects (17.6% vs. 7.7%) and had a greater fat mass reduction in the placebo-controlled trial (5.3% vs. 1.6%). Body weight, fat mass and lean mass were not significantly different between the orlistat- and placebo-treated groups. The orlistat-treated subjects lost an average of 1.6% of their body weight in 6 weeks, and the weight loss was greater with orlistat than with placebo. The orlistat-treated subjects lost an average of 1.1% of their body weight in 6 weeks, and the weight loss was greater with orlistat than with placebo. In conclusion, a clinically-relevant weight-loss program is effective in reducing the weight and fat mass of a male who is obese. The effects of the clinically-relevant weight-loss program on body composition and the non-obese male may help to achieve and maintain a healthy weight.

Citation:Looi A, Lee H, Lim K, Wang Y, Hui M, Lee Y, et al. (2014) Comparison of a clinically-relevant and a non-obese male with obesity on the following metabolic and nutritional parameters: a 12-week study. PLoS ONE 5(4): e0199301. https://doi.org/10.1371/journal.pone.0199301

Editor:Ravi Bhasin, National Heart, Lung and Blood Institute, UNITED STATES

Received:October 1, 2011;Accepted:January 6, 2012;Published:February 13, 2012

Copyright:© 2014 Looi et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability:All relevant data are within the manuscript and its files.

Funding:The study was funded by the National Heart, Lung and Blood Institute, NIH (grant number NIH N01 HD008640). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests:The authors have declared that no competing interests exist.

Introduction

Obesity is one of the most common and strongly associated medical disorders that are a major risk factor for cardiovascular diseases, including hypertension (high blood pressure), high cholesterol (high cholesterol and triglycerides), diabetes, and metabolic syndrome [].

What is the most important information I should know about Orlistat?

You should not use orlistat if you are taking orlistat or if you have taken orlistat for more than 3 months. Your condition may worsen after stopping orlistat. Talk to your doctor or pharmacist before using orlistat if you have liver problems, diabetes, kidney problems, or if you are pregnant or breastfeeding.

What should I discuss with my healthcare provider before using orlistat?

You should not use orlistat if you are taking orlistat or if you have taken for more than 3 months. You should not use orlistat if you have a history of heart failure, liver problems, or if you are breastfeeding.

You should not use orlistat if you are taking orlistat for more than 3 months. Talk to your doctor or pharmacist before using orlistat if you have liver problems, diabetes, kidney problems, or if you are pregnant or breast-feeding.

You should not use orlistat if you are having type 2 diabetes, if you are having any type of surgery, if you are overweight, or if you are taking other medicines called "antidiabetic agents".

What should I do if I forget to give me a too much dose of orlistat?

If you have any of these conditions, tell your doctor before using orlistat:

  • if you are pregnant, plan to become pregnant, or are breast-feeding.
  • if you have any of the following conditions:
  • liver problems, if you are pregnant, or are breast-feeding.
  • kidney problems, if you are taking orlistat or if you have taken for more than 3 months.
  • liver problems, if you are taking orlistat or if you have taken for more than 3 months.
  • kidney problems, if you are pregnant or breast-feeding, or if you are planning to become pregnant.
  • liver problems, if you are breastfeeding, or if you plan to breast-feed.
  • if you are having any surgery.

What should I do if I forget to give me a dose of orlistat?

If you forget a dose of orlistat, use it as soon as you can. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose to catch up.

If you forget to use a dose of orlistat, skip the missed dose and continue with your regular dosing schedule.

Do not give orlistat to children and adolescents under 18 years of age.

Do not give orlistat to people who are pregnant, think they are pregnant, or are breast-feeding.

How should I use orlistat?

Orlistat is taken as a capsule or as a pill. Orlistat can be taken with or without food.